Evommune Inc. EVMN
8.49
(0.31)
(3.52%)
as of 25 Sep
- Market cap
- $309.9M
- P/E
- 0.0×
Follow EVMN
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (141.99%) | 0.00% | 0.00% | 0.00% |
+4 more TTM periods Free account |
|
| (62.71%) | (47.13%) | (61.23%) | (133.69%) | ||
ROIC |
(82.46%) | (60.08%) | (89.61%) | 0.00% | |
Return on Tangible Assets |
(50.25%) | (36.73%) | (50.43%) | (77.95%) | |
Free Cash Flow per Share |
(2.07) | (2.39) | (12.51) | (50.65) | |
Free Cash Flow |
(74.65) | (80.36) | (76.76) | (78.25) | |
Capital Expenditures |
(0.50) | (0.32) | (0.32) | — | |
Piotroski F-Score |
1.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Cash ROIC |
(15.49%) | (15.50%) | (21.54%) | 73.08% | |
Accounts Payable Turnover |
0.00 | — | — | — | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.78 | 1.05 | 1.11 | 1.38 | |
Depreciation/Fixed assets |
0.40 | 0.61 | 1.40 | 1.47 | |
Capex/Depreciation |
(0.76) | (0.32) | (0.23) | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.05) | (2.38) | (12.46) | (50.65) | |
Capex per Share |
(0.01) | (0.01) | (0.05) | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | — | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates